CN101065485B - Lna寡核苷酸和癌症治疗 - Google Patents

Lna寡核苷酸和癌症治疗 Download PDF

Info

Publication number
CN101065485B
CN101065485B CN2005800409084A CN200580040908A CN101065485B CN 101065485 B CN101065485 B CN 101065485B CN 2005800409084 A CN2005800409084 A CN 2005800409084A CN 200580040908 A CN200580040908 A CN 200580040908A CN 101065485 B CN101065485 B CN 101065485B
Authority
CN
China
Prior art keywords
lna
oligonucleotide
seq
nucleotide
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2005800409084A
Other languages
English (en)
Chinese (zh)
Other versions
CN101065485A (zh
Inventor
L·S·卡耶洛夫
M·阿斯克伦德
M·韦斯特加德
C·罗森鲍姆
M·韦森巴赫
B·汉森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
American Businessmen Anlong Pharmaceutical Co Ltd
Original Assignee
American Businessmen Anlong Pharmaceutical Co Ltd
Enzon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Businessmen Anlong Pharmaceutical Co Ltd, Enzon Pharmaceuticals Inc filed Critical American Businessmen Anlong Pharmaceutical Co Ltd
Priority claimed from PCT/DK2005/000719 external-priority patent/WO2006050732A2/en
Publication of CN101065485A publication Critical patent/CN101065485A/zh
Application granted granted Critical
Publication of CN101065485B publication Critical patent/CN101065485B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN2005800409084A 2004-11-09 2005-11-09 Lna寡核苷酸和癌症治疗 Expired - Fee Related CN101065485B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US62656104P 2004-11-09 2004-11-09
DKPA200401728 2004-11-09
US60/626,561 2004-11-09
DKPA200401728 2004-11-09
PCT/DK2005/000719 WO2006050732A2 (en) 2004-11-09 2005-11-09 Lna oligonucleotides and the treatment of cancer

Publications (2)

Publication Number Publication Date
CN101065485A CN101065485A (zh) 2007-10-31
CN101065485B true CN101065485B (zh) 2011-12-07

Family

ID=38965697

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2005800409084A Expired - Fee Related CN101065485B (zh) 2004-11-09 2005-11-09 Lna寡核苷酸和癌症治疗

Country Status (6)

Country Link
CN (1) CN101065485B (de)
AT (1) ATE482271T1 (de)
DE (1) DE602005023772D1 (de)
DK (1) DK1824975T3 (de)
ES (1) ES2353638T3 (de)
ZA (1) ZA200704254B (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107338251A (zh) * 2008-12-04 2017-11-10 库尔纳公司 通过抑制肿瘤抑制基因的天然反义转录物治疗肿瘤抑制基因相关性疾病

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1349541A (zh) * 1999-05-04 2002-05-15 埃克西库恩公司 L－核糖－lna类似物
WO2003091384A2 (en) * 2002-04-24 2003-11-06 Eirx Therapeutics Limited A role for survivin in apoptosis of myeloid cells
WO2004069991A2 (en) * 2003-02-10 2004-08-19 Santaris Pharma A/S Oligomeric compounds for the modulation of survivin expression

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1349541A (zh) * 1999-05-04 2002-05-15 埃克西库恩公司 L－核糖－lna类似物
WO2003091384A2 (en) * 2002-04-24 2003-11-06 Eirx Therapeutics Limited A role for survivin in apoptosis of myeloid cells
WO2004069991A2 (en) * 2003-02-10 2004-08-19 Santaris Pharma A/S Oligomeric compounds for the modulation of survivin expression

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Kurreck J,et al..Design of antisense oligonucleotides stabilized by lockednucleic acids.Nucleic Acids Research30 9.2002,30(9),1911-1918.
Kurreck J,et al..Design of antisense oligonucleotides stabilized by lockednucleic acids.Nucleic Acids Research30 9.2002,30(9),1911-1918. *

Also Published As

Publication number Publication date
ATE482271T1 (de) 2010-10-15
DK1824975T3 (da) 2011-06-06
ZA200704254B (en) 2009-09-30
ES2353638T3 (es) 2011-03-03
CN101065485A (zh) 2007-10-31
ES2353638T9 (es) 2011-06-16
DE602005023772D1 (de) 2010-11-04

Similar Documents

Publication Publication Date Title
CA2586701C (en) Lna oligonucleotides and the treatment of cancer
CN100569945C (zh) 用于调节bcl-2的寡聚化合物
KR101176245B1 (ko) ＨＩＦ－１ａ 발현의 억제를 위한 효능적 ＬＮＡ 올리고뉴클레오티드
CN102851291B (zh) 包含抗微小rna反义寡核苷酸的药物组合物
JP4755972B2 (ja) 短鎖干渉ＲＮＡ（ｓｉＲＮＡ）アナログ
US20040248840A1 (en) Oligomeric compounds for the modulation of ras expression
US20080249039A1 (en) Modified Short Interfering Rna (Modified Sirna)
WO2007031091A2 (en) Rna antagonist compounds for the modulation of p21 ras expression
WO2016006697A1 (ja) アンチセンス抗悪性腫瘍剤
CN101437942A (zh) 包含抗微小rna反义寡核苷酸的药物组合物
CN101065485B (zh) Lna寡核苷酸和癌症治疗
CN101068826B (zh) 有效抑制hif-1a表达的lna寡核苷酸
US20160229883A9 (en) Potent lna oligonucleotides for the inhibition of hif-1a expression
JPWO2019230898A1 (ja) 化学修飾ｓｉＲＮＡとシゾフィランとの複合体を含む医薬組成物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20091016

Address after: Dane Hess Holm

Applicant after: Santa re pharmaceutical company

Co-applicant after: American Businessmen Anlong Pharmaceutical Co., Ltd.

Address before: Holm Hess, Denmark

Applicant before: Enzon Pharmaceuticals Inc

C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20111207

Termination date: 20141109

EXPY Termination of patent right or utility model